PARIS & SAN FRANCISCO, July 16, 2026
Raidium has announced the U.S. launch of Raidium Read (R.Read), an AI-powered oncology imaging workflow platform designed to help cancer centers streamline complex radiology review, improve lesion detection, and enhance clinical research efficiency. The AI-native radiology platform is initially being introduced for oncology research centers and has already been deployed at Moffitt Cancer Center, where it replaces legacy radiomics software with an integrated imaging solution capable of whole-body lesion detection, AI-driven segmentation, and longitudinal lesion tracking across multiple imaging studies. The launch represents a significant advancement in the application of agentic artificial intelligence to radiology, supporting cancer specialists with faster, more accurate imaging analysis while maintaining radiologist oversight. Initially available for clinical trial and oncology research use, the platform is expected to expand into routine clinical practice following planned FDA 510(k) regulatory clearance, reinforcing Raidium’s commitment to transforming oncology imaging through intelligent automation.
AI-Native Platform Enhances Oncology Imaging Workflows
The introduction of Raidium Read addresses one of the most challenging areas in cancer care by simplifying the complex workflow associated with oncology imaging follow-up. The platform integrates whole-body lesion detection, foundation-model-powered AI segmentation, automated RECIST measurements, and longitudinal comparison of imaging studies into a unified clinical viewer, eliminating the need for multiple disconnected software systems. By automating repetitive imaging tasks, the solution significantly reduces manual workload while improving consistency across radiologists. The platform is designed to decrease inter-reader variability by up to threefold, enabling more standardized assessment of tumor progression during oncology clinical trials and routine follow-up. Radiologists also benefit from reduced documentation requirements, improved lesion tracking, and enhanced collaboration during multidisciplinary tumor board discussions, ultimately supporting faster and more informed treatment decisions.
Supporting Cancer Research and Future Clinical Practice
Raidium’s latest deployment demonstrates the growing role of artificial intelligence in oncology research and reflects increasing demand for advanced imaging technologies capable of improving diagnostic precision. The company noted that recent studies continue to highlight the importance of early lesion detection for reducing unnecessary surgical procedures while supporting better patient outcomes. As healthcare organizations seek to modernize radiology workflows, Raidium has developed its platform from the ground up as an AI-native clinical viewer rather than simply adding AI features to legacy imaging systems. This integrated architecture enables seamless workflow automation from image review through clinical reporting while ensuring radiologists remain in complete control of final medical decisions. The solution is currently available for oncology clinical trials and research applications, allowing qualified cancer centers to begin implementation without extensive infrastructure integration.
Advertisement
Regulatory Pathway and Expansion Strategy
Raidium plans to expand the availability of Raidium Read Onco beyond research settings by pursuing FDA 510(k) clearance for selected platform features before the end of 2026. The regulatory strategy is expected to support broader adoption across hospitals, imaging centers, and oncology clinics seeking advanced AI-assisted radiology solutions. Company leadership believes the platform represents a major step toward modernizing cancer imaging by combining foundation AI models, workflow automation, and conversational clinical intelligence within a single environment. With global operations spanning Paris and Silicon Valley, Raidium continues investing in next-generation radiology technologies that improve imaging efficiency while supporting precision oncology and clinical research. As adoption of AI-enabled medical imaging continues to accelerate worldwide, the U.S. launch of Raidium Read positions the company among the innovators driving the future of oncology imaging, clinical trial imaging, and AI-powered healthcare technology, offering cancer centers a scalable solution for more efficient, accurate, and collaborative patient care.
Source: Raidium press release
